Jessica Thor, APRN | |
4265 Meridian St, Bellingham, WA 98226-6492 | |
(360) 200-1650 | |
(360) 200-1652 |
Full Name | Jessica Thor |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Family |
Location | 4265 Meridian St, Bellingham, Washington |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558911719 | NPI | - | NPPES |
Entity Name | Molina Healthcare Of Washington Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912235060 PECOS PAC ID: 1850427527 Enrollment ID: O20100405000336 |
News Archive
Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
Mainstream agencies dealing with heterosexual victims of Domestic Violence and Abuse (DVA) must do more to support and build trust with victims in same sex relationships, researchers of a new book recommend.
When HIV attacks a T cell, it attaches itself to the cell's surface and launches a "harpoon" to create an opening to enter and infect the cells.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Jessica Thor, APRN 4265 Meridian St Ste 104, Bellingham, WA 98226-6492 Ph: (360) 200-1650 | Jessica Thor, APRN 4265 Meridian St, Bellingham, WA 98226-6492 Ph: (360) 200-1650 |
News Archive
Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
Mainstream agencies dealing with heterosexual victims of Domestic Violence and Abuse (DVA) must do more to support and build trust with victims in same sex relationships, researchers of a new book recommend.
When HIV attacks a T cell, it attaches itself to the cell's surface and launches a "harpoon" to create an opening to enter and infect the cells.
› Verified 8 days ago